Adriana Andrade, MD, MPH






Assistant Professor of Medicine

  • Co-chair, ACTG 5350
  • Vice-chair ACTG 5352s
  • Chair, ACTG 5248
  • Protocol Pharmacologist, ACTG 5241
  • Member, Neurology and ARTs Committees
  • Member, Clinical Pharmacology Advisory Group
  • Member, Monoclonal Antibodies Working Group, Adherence Working Group, and Microbiome Focus Group
  • Investigator, End-Organ Disease/Inflammation Transformative Science Group (Dec 2015)
  • Investigator, Antiretroviral Therapy Strategies Subcommittee (Dec 2015-17)
  • Investigator, Study Monitoring Committee of the Antiretroviral Strategies Subcommittee of the SASC (Aug 2016-18)
  • Member, ACTG Mental Health Working Group of the WHISC (Jul 2015-17)
  • Member, NASH Focus Group of the ITSG/HEPTSG (Apr 2016)
  • Andrade ASA, McGruder HF, Wu AW, Celano AC, Skolasky RLJr, Selnes OA, Huang IC, McArthur JC. A programmable device improves adherence to highly antiretroviral therapy in HIV-infected subjects with memory impairment. Clinical Infectious Disease 2005;41:875- 882.
  • Wu AW, Snyder CF, Davis HF, Celano SA, Skolasky RL, Selnes OA, Andrade ASA. A randomized trial of the impact of a programmable medication reminder device on quality of life in patients with AIDS. AIDS Patient Care and STD 2006; 20:773-81.
  • Adriana AS, Hendrix C, Parsons TL, Caballero BH, Yuan CS, Flexner C, Dobs AS, Brown TT. Pharmacokinetic and Metabolic Effects of American Ginseng (Panax quinquefolius) in Healthy Volunteers Receiving the HIV Protease Inhibitor Indinavir. BMC Complementary and Alternative Medicine. 200819;8:50.
  • Andrade AS, Deutsch R, A Celano S, Duarte NA, Marcotte TD, Umlauf A, Atkinson JH, McCutchan JA, Franklin D, Alexander TJ, McArthur JC, Marra C, Grant I, Collier AC. Relationships among neurocognitive status, medication adherence measured by pharmacy refill records, and virologic suppression in HIV-infected persons. J Acquir Immune Defic Syndr. 2013;62:282-92.
  • Andrade A, Rosenkranz SL, Cillo AR, Lu D, Daar ES, Jacobson JM, Lederman M, Acostga EP, Campbell T, Feinberg J, Flexner C, Mellors JW, Kuritzkes DR. Three Distinct Phases of HIV-1 RNA Decay in Treatment-Naive Patients Receiving Raltegravir-Based Antiretroviral Therapy: ACTG A5248. J Infect Dis. 2013;208:884-91.
  • Funderburg NT, Andrade A, Chan ES, Rosenkranz SL, Lu D, Clagett B, Pilch-Cooper HA, Rodriguez B, Feinberg J, Daar E, Mellors J, Kuritzkes D, Jacobson JM, Lederman MM. Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine.  PLOS ONE. December 2013.
  • Spivak A, Andrade A, Eisele E, Hoh R, Bacchetti P, Bumpus NN, Emad F, Buckheit R, McCance-Katz EF, Lai J, Kennedy M, Chande G, Siliciano RF, Siliciano JD, Deeks SG. A Pilot Study Assessing the Safety and Latency Reversing Activity of Disulfiram in HIV-1- Infected Adults on Antiretroviral Therapy. Clin Infect Dis. 2014;58:883-90 (First Co- Author).
  • Havers F, Smeaton L, Detrick B, Gupte N, Bollinger R, Hakim J, Kumarasamy N, Andrade A, Christian P, Lama J, Campbell T, Gupta A. Vitamin D insufficiency and deficiency is associated with HIV progression and death after antiretroviral initiation in resource-limited settings. Accepted, JID, April 2014.


Leadership Committees

Clinical Trials

HPTN083: A Phase 2b/3 Double Blind Safety and Efficacy Study...

HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...

Read More

A5337: Safety and Efficacy of Sirolimus for HIV Reservoir...

When a person becomes infected with HIV the immune system (the system that helps fight infection) is weakened (partly because...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

A5274: REMEMBER, Reducing Early Mortality and Early...

This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More